Abstract
Granulocyte colony-stimulating factor is a potent stimulator for neutrophils in the circulation as well as those progenitors to be increased and be grown in the bone marrow. Recombinant forms of this colony-stimulating factor, therefore, are widely using in the various kinds of clinical fields such as for the treatment of bone marrow suppression after cancer chemotherapy and for the treatment of myelodysplastic disorders. One of the physiological function of granulocyte colony-stimulating factor is to activate neutrophils enough to fight against invaded microbes and others, thus it is hoped to be used for the treatment of various kinds of infectious diseases even while the host has a normal number of circulating neutrophils and normal bone marrow. The future possible clinical usage of granulocyte colony-stimulating factor as for the immunomodulation against various kinds of insults to the human is reviewed.
Keywords: granulocyte colony-stimulating factor, sepsis, bone marrow suppression, myelodysplastic disorders
Current Pharmaceutical Design
Title: Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Volume: 9 Issue: 14
Author(s): Atsuo Murata
Affiliation:
Keywords: granulocyte colony-stimulating factor, sepsis, bone marrow suppression, myelodysplastic disorders
Abstract: Granulocyte colony-stimulating factor is a potent stimulator for neutrophils in the circulation as well as those progenitors to be increased and be grown in the bone marrow. Recombinant forms of this colony-stimulating factor, therefore, are widely using in the various kinds of clinical fields such as for the treatment of bone marrow suppression after cancer chemotherapy and for the treatment of myelodysplastic disorders. One of the physiological function of granulocyte colony-stimulating factor is to activate neutrophils enough to fight against invaded microbes and others, thus it is hoped to be used for the treatment of various kinds of infectious diseases even while the host has a normal number of circulating neutrophils and normal bone marrow. The future possible clinical usage of granulocyte colony-stimulating factor as for the immunomodulation against various kinds of insults to the human is reviewed.
Export Options
About this article
Cite this article as:
Murata Atsuo, Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis, Current Pharmaceutical Design 2003; 9 (14) . https://dx.doi.org/10.2174/1381612033454982
DOI https://dx.doi.org/10.2174/1381612033454982 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Therapeutic Antibodies
Current Molecular Medicine Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Anti-Cancer Agents in Medicinal Chemistry mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry ACE2 and Diabetic Complications
Current Pharmaceutical Design The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Current Medicinal Chemistry Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Epigenetics in Brain Tumors: HDACs Take Center Stage
Current Neuropharmacology Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Cancer Neovascularization and Proinflammatory Microenvironments
Current Cancer Drug Targets Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Proteasomes as Drug Targets
Current Drug Targets Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Current Cancer Drug Targets Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design